Skip to main content

User account menu

  • Safety Data
  • Package Inserts

Main navigation

  • Women's Health Products
    • Breast Health
    • Gynecological Health
    • Sexual Health
    • Body Composition
    • Skeletal Health
  • Lab Technologies
    • Tests
    • Cytology
    • Molecular Diagnostics
    • Collection Devices
    • Screening Technologies
  • About
    • Hologic Highlights
    • Coronavirus Update
    • Investor Relations
    • Media Library
    • Events
    • Sustainability
    • Global Access Initiative
    • Philanthropy
    • Project Health Equality
    • Hologic Timeline
    • Real Women's Stories
    • Well Woman
    • Locations
  • Support
    • Safety Data Sheets
    • Package Inserts
    • Contact
    • Medical Education
    • Order Online (iStore)
    • Contact our Compliance Hotline
  • Careers
  • Women's Health Index

Second top menu

  • Women's Health Index
  • Investors
  • Careers
  • Contact us
  • Sign in

Site selector

  • Country: USA
    • Canada
    • China
    • France
    • Germany
    • Italy
    • Japan
    • Netherlands

Site selector

  • Country: USA
    • Canada
    • China
    • France
    • Germany
    • Italy
    • Japan
    • Netherlands

User account menu

  • Safety Data
  • Package Inserts

Second top menu

  • Women's Health Index
  • Investors
  • Careers
  • Contact us
  • Sign in
Home

Main navigation (Header)

  • Women's Health Products
    • Breast Health
    • Gynecological Health
    • Sexual Health
    • Body Composition
    • Skeletal Health
  • Lab Technologies
    • Tests
    • Cytology
    • Molecular Diagnostics
    • Collection Devices
    • Screening Technologies
  • About
    • Hologic Highlights
    • Coronavirus Update
    • Investor Relations
    • Media Library
    • Events
    • Sustainability
    • Global Access Initiative
    • Philanthropy
    • Project Health Equality
    • Hologic Timeline
    • Real Women's Stories
    • Well Woman
    • Locations
  • Support
    • Safety Data Sheets
    • Package Inserts
    • Contact
    • Medical Education
    • Order Online (iStore)
    • Contact our Compliance Hotline
  • Careers
  • Women's Health Index
Home
Back to Products

Aptima® HPV +ThinPrep® Cervical Health

Find Support
Placeholder image
    Overview

    Leading the charge in cervical disease prevention with the ThinPrep® system and Aptima® HPV assays

    Hologic has remained an unwavering advocate for women’s health for more than two decades. Our goals as a company are intrinsically tied to changes in best-practices for women’s health, applying the latest findings in diagnostic medicine to the development of new products and technologies in response to the emergence of new discoveries in medicine.

    Cervical disease screening is an essential component of our efforts in women’s health. Hologic is the leader in Pap and human papillomavirus (HPV) testing. The ThinPrep® Pap test helps healthcare providers detect the presence of abnormal cervical cells, and the Aptima HPV assays identify high-risk HPV mRNA that is indicative of the HPV infections most likely to lead to cervical disease.1-3

      The path to defeating cervical cancer

      Today, screening with Pap+HPV Together™ (co-testing) provides the best possible protection against cervical cancer for women ages 30-65.4-6 Now, what was once a top cancer among women is up to 93% preventable.7 

      The introduction of the Pap smear and later, the ThinPrep Pap test, have contributed to a decline in cervical cancer rates of more than 60% since the 1950s.1,8 Since then, HPV has been identified as a cause of cervical cancer, and HPV testing and vaccinations have been developed.9

      These medical triumphs have fortified the medical community’s ability to detect and prevent cervical disease and cancer. Today, the combination of data-supported guidelines for cervical cancer screening and the availability of HPV vaccination are key in the fight for cervical health. 

      Cervical cancer screening guidelines help mitigate risk

      The American Congress of Obstetricians and Gynecologists (ACOG) delivers guidelines for cervical cancer screening. For women ages 30-65, this means Pap+HPV Together.6 

      ACOG recommends:

      • Pap-alone screening for women ages 21-29.6
      • Co-testing for women ages 30-65.6 

      At Hologic, we believe in delivering precision testing that helps women live healthier without enduring a disease that is largely preventable with accurate screening.7 Our tests are designed to help providers Be Sure when it comes to screening. The ThinPrep Pap test is the most widely used Pap test in the United States.10 The Aptima HPV assays identify high-risk HPV infections by targeting E6/E7 mRNA.2,3

      The ThinPrep Pap test: First in liquid-based cytology

      Hologic released the first FDA-approved, liquid-based cytology option in cervical disease screening in 1996: the ThinPrep Pap test.1 Today, more than 20 years after the release of the ThinPrep Pap test, it remains the preferred choice in Pap testing in the United States.10 ThinPrep Pap tests account for more than 80% of Pap tests performed in the United States, with 650 million tests performed globally so far.10 

      More than 170 scientific studies involving the ThinPrep Pap test have demonstrated its benefits, including increased disease detection, reduction of equivocal diagnoses, improved specimen adequacy, adjunctive molecular testing and morphology assessment.11

      The College of American Pathologists reported increased HSIL (high-grade squamous intraepithelial lesions) and LSIL (low-grade squamous intraepithelial lesions) in labs using liquid-based cytology versus labs that used conventional Pap testing.12 It also showed increased sensitivity for cervical adenocarcinoma over conventional Pap testing.13

      The ThinPrep Pap test is the only liquid-based Pap test FDA approved for use with all current FDA-approved HPV tests.* It is also FDA cleared for chlamydia, gonorrhea and trichomoniasis testing from the same vial.1,14

      HPV testing for precision detection and risk stratification

      The Aptima® HPV assay and Aptima® HPV 16 18/45 genotype assay target HPV types that pose the largest threat to women.2,3 While other HPV assays target DNA, the Aptima HPV assays target mRNA, which studies show reflects the presence and activity of high-risk HPV infection.2,3 The Aptima HPV assay detects E6/E7 mRNA, which is indicative of those HPV infections more likely to cause cervical disease.2 The Aptima HPV 16 18/45 genotype assay identifies HPV types 16, 18 and 45, which are associated with up to 80% of all invasive cervical cancers worldwide.3,15-16 

      Screening women with Aptima HPV assays helps providers optimize care for each patient.

      The ThinPrep system helps optimize lab workflow

      The ThinPrep Pap test is just one of several offerings in the ThinPrep system. The ThinPrep processors, imagers and review scopes help improve workflow in laboratories and assist with cytotechnologists’ ability to identify abnormalities. These instruments help complete the ThinPrep system and maximize laboratory efficiency and accuracy in disease detection.

      In addition to the ThinPrep Pap test, Hologic remains committed to providing laboratories with innovative and effective cytology solutions for non-gynecological testing needs.

      Processors

      ThinPrep Genesis Processor

      The next-generation in single sample processing, but with ergonomic, chain of custody benefits and aliquoting capabilities

      Placeholder image

      ThinPrep 5000 Processor

      Offers fully automated, small-batch processing and provides operators flexibility, along with walkaway time

      Placeholder image

      ThinPrep 5000 Autoloader

      Maximizes laboratory efficiency with fully automated, large-batch processing with automatic slide patient ID etching

      Placeholder image

      Imagers and Review Scopes

      • Now Available ThinPrep Integrated Imager®: Combines the power of ThinPrep imaging and manual microscope review in a single desktop system, with slides imaged and ready for review in approximately 90 seconds.
      • ThinPrep® Image Processor: Identifies 22 areas of interest within the ThinPrep Pap test slides with the largest, darkest nuclei for cytotechnologists to examine.
      • ThinPrep® Imager Duo: Same trusted algorithm as the ThinPrep image processor, but with a faster camera, expanded label-reading formats and on-demand imaging.
      • ThinPrep® Review Scope: Presents the 22 fields of view to the cytotechnologist for their review.
      • ThinPrep® Review Scope Manual+: Combines the power of the review scope with the flexibility of a manual microscope.

      Stainers

      Now Available Compass Stainer: Adds flexibility to both routine and special staining procedures. Comes programmed with the ThinPrep Stain Protocol for customer convenience.

      From Pap and HPV testing to our full range of diagnostic products and cross-divisional innovations like the Genius™ 3D Mammography™ exam for breast health, Hologic delivers for women. Our promise to offer innovative products to meet the needs of women globally persists throughout all that we do, including in cervical disease screening. Working together, we can achieve the goal of defeating cervical disease.

      A multifaceted approach for women’s holistic health

      To learn more about the Aptima + ThinPrep Cervical Health portfolio, visit HealthDxS.com.

      Placeholder image

      Find Support

      All Other Requests

      * Aptima HPV assay, Aptima HPV 16 18/45 Genotype assay, Cervista HPV HR test, Cervista HPV 16/18 test, Roche cobas HPV test and Hybrid Capture 2 HPV DNA test.

      References: 1. ThinPrep 2000 Processor [instructions for use]. MAN-02624-001, Rev. 005. Marlborough, MA: Hologic, Inc.; 2017.  2. Aptima HPV assay [package insert]. AW-12820-001, Rev. 001. San Diego, CA: Hologic, Inc.; 2015.  3. Aptima HPV Genotype 16 18/45 assay [package insert]. AW-12821-001, Rev. 001. San Diego, CA: Hologic, Inc.; 2015.  4. Blatt AJ, et al. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123(5):282-288 [Study included ThinPrep®, SurePath®, Hybrid Capture® 2 assay].  5. Saslow D, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012; 62(3):147-172.  6. The American College of Obstetricians and Gynecologists. Practice Bulletin 168: Screening for cervical cancer. Obstet Gynecol. 2016;128(4):3111-30. doi:10.1097/ AOG.0000000000001708.  7. Centers for Disease Control and Prevention. Cervical Cancer is Preventable. https://www.cdc.gov/vitalsigns/cervical-cancer/index.html. Updated November 5, 2014. Accessed November 29, 2017.  8. National Cancer Institute. SEER Stat Fact Sheets: Cervix Uteri Cancer. http://seer.cancer.gov/statfacts/html/cervix.html. Published 2016. Accessed December 4, 2017.  9. National Institutes of Health. NIH Fact Sheets: Cervical Cancer. http://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=76. Updated March 29, 2013. Accessed November 29, 2017.  10. Hologic, Inc. Data on File.  11. Hologic, Inc. View Published Data: Direct-to-Vial Studies. https://healthdxs.com/en/view-published-data/. Accessed November 29, 2017.  12. Eversole GM, et al. Practices of participants in the College of American Pathologists interlaboratory comparison program in cervicovaginal cytology, 2006. Arch Pathol Lab Med. 2010;134(3):331-5. doi:10.1043/1543-2165-134.3.331.  13. Adegoke O, et al. Cervical Cancer Trends in the United States: A 35-Year Population-Based Analysis. J Women Health. 2012;21(10):1031-1037.  14. PrepStain System [product insert]. 779-07085-00, Rev. F. Burlington, NC: TriPath Imaging, Inc., 2011.  15. Li N, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 128:927-935. doi:10.1002/ijc.25396.  16. De Sanjose S, et al. 2010. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet. doi:10.1016/S1470-2045(10)70230-8.
      Package Inserts

      Aptima®+ThinPrep® Cervical Health Safety Data Sheets

      Learn More

      Cytologystuff.com

      Related Products

      Aptima® Virology

      Aptima® Virology

      Aptima® STIs

      Aptima® STIs

      Perinatal

      Perinatal

      Panther® Scalable Solutions

      Panther® Scalable Solutions

      Back to Products

      Aptima® HPV +ThinPrep® Cervical Health

      Find Support
      Placeholder image
        Overview

        Leading the charge in cervical disease prevention with the ThinPrep system and Aptima HPV assays

        Hologic has remained an unwavering advocate for women’s health for more than two decades. Our goals as a company are intrinsically tied to changes in best-practices for women’s health, applying the latest findings in diagnostic medicine to the development of new products and technologies in response to the emergence of new discoveries in medicine.

        Cervical disease screening is an essential component of our efforts in women’s health. Hologic is the leader in Pap and human papillomavirus (HPV) testing. The ThinPrep Pap test helps healthcare providers detect the presence of abnormal cervical cells, and the Aptima HPV assays identify high-risk HPV mRNA that is indicative of the HPV infections most likely to lead to cervical disease.1-3

          The path to defeating cervical cancer

          Today, screening with Pap+HPV Together (co-testing) provides the best possible protection against cervical cancer for women ages 30-65.4-6 Now, what was once a top cancer among women is up to 93% preventable.7

          The introduction of the Pap smear and, later the ThinPrep Pap test, have contributed to a decline in cervical cancer rates of more than 60% since the 1950s.1,8 Since then, HPV has been identified as a cause of cervical cancer, and HPV testing and vaccinations have been developed.9

          These medical triumphs have fortified the medical community’s ability to detect and prevent cervical disease and cancer. Today, the combination of data-supported guidelines for cervical cancer screening and the availability of HPV vaccination are key in the fight for women’s health.

          The ThinPrep Pap test: First in liquid-based cytology

          Hologic released the first liquid-based cytology option in cervical disease screening in 1996: the ThinPrep Pap test.1 Today, more than 20 years after the release of the ThinPrep Pap test, it remains the preferred choice in Pap testing in the United States.10 ThinPrep Pap tests account for more than 80% of Pap tests performed in the United States, with 650 million tests performed globally so far.10

          More than 170 scientific studies involving the ThinPrep Pap test have demonstrated its benefits, including increased disease detection, reduction of equivocal diagnoses, improved specimen adequacy, adjunctive molecular testing and morphology assessment.11

          The College of American Pathologists reported increased HSIL (high-grade squamous intraepithelial lesions) and LSIL (low-grade squamous intraepithelial lesions) in labs using LBC versus labs that utilized conventional Pap testing.12 It also showed increased sensitivity for cervical adenocarcinoma over conventional Pap testing.13

          HPV testing for precision detection and risk stratification

          The Aptima HPV assay and Aptima HPV 16 18/45 genotype assay target HPV types that pose the largest threat to women.2,3 While other HPV assays target DNA, the Aptima HPV assays target mRNA, which studies show reflects the presence and activity of high-risk HPV infection.2,3 The Aptima HPV assay detects E6/E7 mRNA, which is indicative of those HPV infections more likely to cause cervical disease.2 The Aptima HPV 16 18/45 genotype assay identifies HPV types 16, 18 and 45, which are associated with up to 80% of all invasive cervical cancers worldwide.3,14-15

          Screening women with Aptima HPV assays helps providers optimize care for each patient.

          The ThinPrep system helps optimize lab workflow

          The ThinPrep Pap test is just one of several offerings in the ThinPrep system. The ThinPrep processors, imagers and review scopes help improve workflow in laboratories and assist with cytotechnologists’ ability to identify abnormalities. These instruments help complete the ThinPrep system and maximize laboratory efficiency and accuracy in disease detection.

          In addition to the ThinPrep Pap test, Hologic remains committed to providing laboratories with innovative and effective cytology solutions for non-gynecological testing needs.

          Processors

          ThinPrep Genesis Processor

          The next-generation in single sample processing, but with ergonomic, chain of custody benefits and aliquoting capabilities

          Placeholder image

          ThinPrep 5000 Processor

          Offers fully automated, small-batch processing and provides operators flexibility, along with walkaway time

          Placeholder image

          ThinPrep 5000 Autoloader

          Maximizes laboratory efficiency with fully automated, large-batch processing with automatic slide patient ID etching

          Placeholder image

          Imagers and Review Scopes

            Now Available ThinPrep Integrated Imager®:

            Combines the power of ThinPrep imaging and manual microscope review in a single desktop system, with slides imaged and ready for review in approximately 90 seconds.

            ThinPrep® Image Processor:

            Identifies 22 areas of interest within the ThinPrep Pap test slides with the largest, darkest nuclei for cytotechnologists to examine.

            ThinPrep® Imager Duo:

            Same trusted algorithm as the ThinPrep image processor, but with a faster camera, expanded label-reading formats and on-demand imaging.

            ThinPrep® Review Scope:

            Presents the 22 fields of view to the cytotechnologist for their review.

            ThinPrep® Review Scope Manual+:

            Combines the power of the review scope with the flexibility of a manual microscope.

            Stainers

             

            Now Available Compass Stainer: Adds flexibility to both routine and special staining procedures. Comes programmed with the ThinPrep Stain Protocol for customer convenience.

            From Pap and HPV testing to our full range of diagnostic products and cross-divisional innovations like the Genius™ 3D Mammography exam for breast health, Hologic delivers for women. Our promise to offer innovative products to meet the needs of women globally persists throughout all that we do, including in cervical disease screening. Working together, we can achieve the goal of defeating cervical disease.

            Find Support

            All Other Requests

            References: 1. ThinPrep 2000 Processor [instructions for use]. MAN-02624-001, Rev. 005. Marlborough, MA: Hologic, Inc.; 2017.  2. Aptima HPV assay [package insert]. AW-12820-001, Rev. 001. San Diego, CA: Hologic, Inc.; 2015.  3. Aptima HPV Genotype 16 18/45 assay [package insert]. AW-12821-001, Rev. 001. San Diego, CA: Hologic, Inc.; 2015.  4. Blatt AJ, et al. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123(5):282-288 [Study included ThinPrep®, SurePath®, Hybrid Capture® 2 assay].  5. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012; 62(3):147-172.  6. The American College of Obstetricians and Gynecologists. Practice Bulletin 168: Screening for cervical cancer. Obstet Gynecol. 2016;128(4):3111-30. doi:10.1097/ AOG.0000000000001708.  7. Centers for Disease Control and Prevention. Cervical Cancer is Preventable. https://www.cdc.gov/vitalsigns/cervical-cancer/index.html. Updated November 5, 2014. Accessed November 29, 2017.  8. National Cancer Institute. SEER Stat Fact Sheets: Cervix Uteri Cancer. http://seer.cancer.gov/statfacts/html/cervix.html. Published 2016. Accessed December 4, 2017.  9. National Institutes of Health. NIH Fact Sheets: Cervical Cancer.  http://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=76. Updated March 29, 2013. Accessed November 29, 2017.  10. Hologic, Inc. Data on File.  11. Hologic, Inc. View Published Data: Direct-to-Vial Studies. https://healthdxs.com/en/view-published-data/. Accessed November 29, 2017.  12. Eversole GM, et al. Practices of participants in the College of American Pathologists interlaboratory comparison program in cervicovaginal cytology, 2006. Arch Pathol Lab Med. 2010;134(3):331-5. doi:10.1043/1543-2165-134.3.331.  13. Adegoke O, et al. Cervical cancer Trends in the United States: A 35-Year Population-Based Analysis. J Women Health. 2012;21(10):1031-1037.  14. Li N, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 128:927-935. doi:10.1002/ijc.25396.  15. De Sanjose S, et al. 2010. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet. doi:10.1016/S1470-2045(10)70230-8.
            Package Inserts

            Package Inserts

            Package Inserts

            Related Products

            Aptima® Virology

            Aptima® Virology

            Aptima® STIs

            Aptima® STIs

            Perinatal

            Perinatal

            Panther® Scalable Solutions

            Panther® Scalable Solutions

            Main navigation (Footer)

            • Women's Health Products
              • Breast Health
              • Gynecological Health
              • Sexual Health
              • Body Composition
              • Skeletal Health
            • Lab Technologies
              • Tests
              • Cytology
              • Molecular Diagnostics
              • Collection Devices
              • Screening Technologies
            • About
              • Hologic Highlights
              • Coronavirus Update
              • Investor Relations
              • Media Library
              • Events
              • Sustainability
              • Global Access Initiative
              • Philanthropy
              • Project Health Equality
              • Hologic Timeline
              • Real Women's Stories
              • Well Woman
              • Locations
            • Support
              • Safety Data Sheets
              • Package Inserts
              • Contact
              • Medical Education
              • Order Online (iStore)
              • Contact our Compliance Hotline
            • Careers
            • Women's Health Index
            Hologic footer logo

            © Copyright 2022 Hologic, Inc. All rights reserved.

            Health logo

            Footer menu

            • Privacy Policy
            • Terms & Conditions
            • Patent Info
            • AdvaMed Code of Ethics
            • International Modern Slavery Statement

            Footer social links

            • Twitter
            • Linkedin
            • Facebook
            • Glassdoor
            • Youtube
            • Instagram